Journals / Retina-Vitreus / 2007 / Cilt: 15 - Sayı: 4

Tamoxifen retinopathy in low-dose therapy

Düşük doz kullanımda tamoksifen retinopatisi

Pages
283–286
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Tamoxifen retinopathy should be kept in mind in the differential diagnosis of diseases causing crystalline deposition and changes in retinal pigment epithelium.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 53-year-old woman with breast cancer for 12 years who was on tamoxifen therapy (20 mg/day) for the last 4 years was referred to our clinic for her yearly ophthalmic examination.
📊
Key Findings & Data:Visual acuity was 10/10 in both eyes and no pathology was found in the anterior segment examination.
💡
Conclusion & Impact:Tamoxifen retinopathy should be kept in mind in the differential diagnosis of diseases causing crystalline deposition and changes in retinal pigment epithelium.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İlaç toksisitesi · Kadın · Floresan anjiyografi

Abstract

A 53-year-old woman with breast cancer for 12 years who was on tamoxifen therapy (20 mg/day) for the last 4 years was referred to our clinic for her yearly ophthalmic examination. Visual acuity was 10/10 in both eyes and no pathology was found in the anterior segment examination. The funduscopy showed small yellow-white crystalline depositions and retinal pigment epithelium changes at the level of the inner retina all around the macula and posterior pole. Fluorescein angiography demonstrated hyperfluorescence due to a window defect and hypofluorescence because of choroidal atrophy and on the late frames dense hyperfluorescence caused by the depositions. Optical coherence tomography showed no macular edema or thickening. Tamoxifen rarely causes retinopathy in low-dose therapy (20 mg/day). The drug may cause severe changes in fundus appearance and angiography although visual acuity may not be affected. Tamoxifen retinopathy should be kept in mind in the differential diagnosis of diseases causing crystalline deposition and changes in retinal pigment epithelium.

Özet

Oniki yıldır meme Ca nedeniyle takip edilen 53 yaşında bayan hasta, son 4 yıl günde 20mg tamoksifen kullanması nedeniyle senelik göz muayenesi için kliniğimize başvurdu. Hastanın yapılan göz muayenesinde her iki gözde görme- ler tam olarak ölçüldü. Biomikroskopik muayenede, kornea ve ön segment her iki gözde doğal olarak değerlendirildi. Fundus muayenesinde, özellikle makula çevresinde ve tüm arka kutupta iç retina yerleşimli küçük sarı, beyaz kristal- lin depozitler ile birlikte retina pigment epitel düzensizliği gözlendi. Floresein anjiografide, fovea çevresinde pencere defektine bağlı hiper ve koroid atrofisine bağlı hipoflore- san alanlar ile ileri evrede, maküla çevresinde depozitlerin boyanmasına bağlı yoğun hiperfloresans gözlendi. Optik koherens tomografide maküla ödemi veya retinal kalınlaş- maya rastlanmadı. Tamoksifen, düşük doz (20mg/gün) kullanıldığında nadi- ren retinopatiye yol açan bir ilaçtır. Retinopati durumunda görme keskinliği etkilenmese de, fundus görünümünde ve anjiyografide önemli ölçüde ve kalıcı değişikliklere neden olabilmektedir. Bu bulgular, diğer retina pigment epitel bozukluğu yapan hastalıkların ayırıcı tanısında akla getiril- melidir.

🔖

Cite This Article

ASLAN, Ö., TIRHIŞ, H., BATMAN, C., ZİLELİOĞLU, O. (2007). Tamoxifen retinopathy in low-dose therapy. Retina-Vitreus, Cilt: 15 - Sayı: 4, 283–286. https://ajindex.com/articles/307794

References (9)

  1. Kaiser-Kupfer MI, Lippman ME: Tamoxifen retinopathy. Cancer Treat Rep. 1978;62:315-320
  2. Heier JS, Dragoo RA, Enzenauer RW, et al.: Screening for ocu- lar toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol. 1994;117:772-775
  3. No authors listed. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31.000 recurrences and 24.000 deaths among 75.000 women. Early Breast Cancer Trialists’ Collaborative Group. Lan- cet. 1992;339:71-85
  4. Sadowski B, Kriegbaum C, Apfelstedt-Sylla E: Tamoxifen side ef- fects, age-related macular degeneration (AMD) or cancer associ- ated retinopathy (CAR)?. Eur J Ophthalmol. 2001;11:309-312
  5. Parkkari M, Paakkala M, Salminen L, Holli K: Ocular side-effects in breast cancer patients treated with tamoxifen and toremife- ne: a randomized follow-up study. Acta Ophthalmol Scand. 2003;81:495-499
  6. Imperia PS, Lazarus HM, Lass JH: Ocular complications of syste- mic cancer chemotherapy. Surv Ophthalmol. 1989;34:209- 230
  7. Chern S, Danis RP: Retinopathy associated with low-dose tamoxi- fen. Am J Ophthalmol. 1993;116:372-373
  8. Gerner EW: Ocular toxicity of tamoxifen. Ann Ophthalmol. 1989;21:420-423
  9. Gualino V, Cohen SY, Delyfer MN, et al.: Optical coherence to- mography findings in tamoxifen retinopathy. Am J Ophthalmol. 2005;140:757-758.